Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier
A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.
1. A method for treating an ocular condition associated with neovascularization of the eye in a patient, the method comprising administering an extruded biodegradable intraocular implant to the patient by intravitreal injection, wherein the extruded biodegradable intraocular implant consists of:
a) about 70-85% by weight of a biodegradable polymeric carrier, wherein the biodegradable polymeric carrier is a poly-lactide-co-glycolide (PLGA);
b) about 10-20% by weight of an anti-VEGF antibody; and
c) about 5-10% by weight of a saturated straight chain alcohol 16 to 26 carbon atoms in length.
2. The method of claim 1 , wherein the anti-VEGF antibody is bevacizumab.
3. The method of claim 1 , wherein the ocular condition is choroidal neovascularization.
4. The method of claim 1 , wherein the implant is administered to the patient via a needle.
5. The method of claim 1 , wherein said saturated straight chain alcohol is 1-eicosanol.